- Transgenomic (TBIO +5.6%) announces its first license for commercialization rights to its Multiplexed ICE COLD-PCR (MX-ICP) technology to the University of Melbourne for a number of research and commercial applications.
- Under the terms of the agreement, Melbourne receives an exclusive license in Australia to the company's four EGFR liquid biopsy cancer assays which detect specific actionable mutations associated with sensitivity or resistance to targeted drugs used in treating colorectal and non-small cell lung cancer in a variety of sample types, including blood and plasma. Financial terms of the contract are not disclosed.
-
MX-ICP is a high sensitivity DNA amplification technology that can detect mutations in any liquid sample (liquid biopsy).